Patent · US Expired

Antiviral therapy using thiazine dyes

US6346529B1 · kind B1 · utility

21Cited by
16References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 15, 1998
Grant dateFeb 12, 2002
Priority date
Expiry dateApr 15, 2018

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61M1/3683
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses, especially human immunodeficiency virus. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine blue O, and thionine. The preferred dye at this time is methylene blue. Methylene blue is FDA approved for topical, i.v., and oral administration, and has minimal side effects. Since methylene blue absorbs in the red wavelengths, i.e., approximately 670 nm, which penetrates tissue much better than other lower wavelengths, light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.